Acadia Pharmaceuticals
ACAD
297 hedge funds and large institutions have $7.4B invested in Acadia Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 79 funds opening new positions, 80 increasing their positions, 95 reducing their positions, and 26 closing their positions.
204% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 26
21% more funds holding
Funds holding: 246 → 297 (+51)
14% more capital invested
Capital invested by funds: $6.51B → $7.4B (+$890M)
1.23% less ownership
Funds ownership: 99.26% → 98.03% (-1.2%)
14% less call options, than puts
Call options by funds: $39.2M | Put options by funds: $45.6M
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
16% less repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 95
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$116M |
| 2 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
+$43.2M |
| 3 |
D.E. Shaw & Co
New York
|
+$41.2M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$30M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$27.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$114M |
| 2 |
State Street
Boston,
Massachusetts
|
-$70.8M |
| 3 |
HM
HealthCor Management
New York
|
-$57.9M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$46M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$42.9M |
ACAD Hedge Fund Activity: Q2 2020 in Review
297 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q2 2020, worth a combined $7.4B — up 14% from $6.51B a quarter earlier.
Buyers outnumbered sellers: 79 funds opened new ACAD positions and 26 closed out — a net gain of 53 holders — while 80 added to existing stakes and 95 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $116M. The largest seller was BlackRock, cutting an estimated $114M.
- 297 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q2 2020, up from 246 in Q1 2020.
- Funds reported $7.4B of Acadia Pharmaceuticals stock for Q2 2020, up 14% quarter-over-quarter.
- 79 funds opened new Acadia Pharmaceuticals positions in Q2 2020 and 26 closed out, a net change of +53 holders.
- The largest Acadia Pharmaceuticals buyer in Q2 2020 was Janus Henderson Group, an estimated $116M added.
- The largest Acadia Pharmaceuticals seller in Q2 2020 was BlackRock, an estimated $114M sold.
Based on aggregated 13F filings for Q2 2020.